BeiGene, Ltd.

BeiGene, Ltd.verified

BGNE

Price:

$161.94

Market Cap:

$17.78B

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and ...[Read more]

Industry

Biotechnology

IPO Date

2016-02-03

Stock Exchange

NASDAQ

Ticker

BGNE

The PE Ratio as of July 2024 (TTM) for BeiGene, Ltd. (BGNE) is -21.45

According to BeiGene, Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -21.45. This represents a change of 248.21% compared to the average of -6.16 of the last 4 quarters.

BeiGene, Ltd. (BGNE) Historical PE Ratio (quarterly & annually)

How has BGNE PE Ratio performed in the past?

The mean historical PE Ratio of BeiGene, Ltd. over the last ten years is -24.11. The current -21.45 PE Ratio has changed 8.80% with respect to the historical average. Over the past ten years (40 quarters), BGNE's PE Ratio was at its highest in in the March 2021 quarter at 119.69. The PE Ratio was at its lowest in in the December 2014 quarter at -99.40.

Quarterly (TTM)
Annual

Average

-24.11

Median

-14.55

Minimum

-81.59

Maximum

-10.10

BeiGene, Ltd. (BGNE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of BeiGene, Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 373.06%

Maximum Annual PE Ratio = -10.10

Minimum Annual Increase = -80.84%

Minimum Annual PE Ratio = -81.59

Quarterly (TTM)
Annual
YearPE RatioChange
2023-21.3588.63%
2022-11.32-36.36%
2021-17.7931.99%
2020-13.4828.68%
2019-10.47-9.27%
2018-11.54-75.86%
2017-47.80373.06%
2016-10.10-35.35%
2015-15.63-80.84%
2014-81.59-59.00%

BeiGene, Ltd. (BGNE) Average PE Ratio

How has BGNE PE Ratio performed in the past?

The current PE Ratio of BeiGene, Ltd. (BGNE) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-16.82

5-year avg

-14.88

10-year avg

-24.11

BeiGene, Ltd. (BGNE) PE Ratio vs. Peers

How is BGNE’s PE Ratio compared to its peers?

BeiGene, Ltd.’s PE Ratio is less than Ascendis Pharma A/S (-13.92), less than Apellis Pharmaceuticals, Inc. (-11.00), less than Akero Therapeutics, Inc. (-8.90), greater than Blueprint Medicines Corporation (-24.49), less than I-Mab (-0.53), less than Krystal Biotech, Inc. (101.82), less than Immunovant, Inc. (-15.53), less than Mirati Therapeutics, Inc. (-5.32), less than Incyte Corporation (20.06), less than BioMarin Pharmaceutical Inc. (77.55), greater than ImmunoGen, Inc. (-122.93), greater than Prometheus Biosciences, Inc. (-81.93), less than Arrowhead Pharmaceuticals, Inc. (-7.46), less than Ionis Pharmaceuticals, Inc. (-19.08), greater than Legend Biotech Corporation (-23.15), greater than Vaxcyte, Inc. (-21.55), less than Travere Therapeutics, Inc. (-4.62),

Build a custom stock screener for BeiGene, Ltd. (BGNE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BeiGene, Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BeiGene, Ltd. (BGNE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BeiGene, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is BeiGene, Ltd.'s PE Ratio?

How is the PE Ratio calculated for BeiGene, Ltd. (BGNE)?

What is the highest PE Ratio for BeiGene, Ltd. (BGNE)?

What is the 3-year average PE Ratio for BeiGene, Ltd. (BGNE)?

What is the 5-year average PE Ratio for BeiGene, Ltd. (BGNE)?

How does the current PE Ratio for BeiGene, Ltd. (BGNE) compare to its historical average?